title: Therapeutic approaches to target inflammation in type 2 diabetes.
abstract: BACKGROUND
  Chronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states.
  
  
  BACKGROUND
  Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates.
  
  
  CONCLUSIONS
  The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity.
authors.affiliation: Joslin Diabetes Center, Harvard Medical School, Boston, MA 02115, USA. allison.goldfine@joslin.harvard.edu
authors.forename: Allison B
authors.initials: AB
authors.lastname: Goldfine
authors.forename: Vivian
authors.initials: V
authors.lastname: Fonseca
authors.forename: Steven E
authors.initials: SE
authors.lastname: Shoelson
mesh_terms: D000273:Adipose Tissue / Q000503:physiopathology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D012459:Salicylates / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D012459:Salicylates